Top

Infection

Published in:

01-08-2018 | Original Paper

Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study

Authors: Basima A. Almomani, Wail A. Hayajneh, Abeer M. Ayoub, Mera A. Ababneh, Miral A. Al Momani

Published in: Infection | Issue 4/2018

Abstract

Purpose

To assess incidence rate, risk factors and susceptibility patterns associated with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or Klebsiella pneumoniae in community-acquired urinary tract infections (CA-UTIs).

Methods

A prospective, case-control study was conducted at a tertiary teaching hospital from Jan 2015 to Dec 2016. The results of microbiology cultures were initially screened to include only patients with positive E. coli or K. pneumoniae urine cultures. Afterwards, clinical symptoms were assessed to confirm the UTI. To investigate the risk factors, patients with a positive urine culture for ESBL-producing isolates were assigned as cases, while patients with non-ESBL were assigned as controls.

Results

Out of 591 patients included in this study, 57.5% (n = 340) were included in the control group and 42.5% (n = 251) were in the case group. The incidence rate of ESBL-producing isolates was 3.465 cases per 1000-patient hospital admissions. Male gender (OR = 1.856, 95% CI = 1.192–2.889, p = 0.006), pediatrics (OR = 1.676, 95% CI = 1.117–2.517, p = 0.013), patients with comorbidity (OR = 1.542, 95% CI = 1.029–2.312, p = 0.036) and UTI in the previous 12 months (OR = 1.705, 95% CI = 1.106–2.628, p = 0.016) were independently associated with a higher risk of infection. The resistance rate for most commonly prescribed antibiotics was high.

Conclusions

Our results suggest that the incidence of ESBL producers among CA-UTIs is high. Male gender, pediatrics, comorbidity and UTI in the previous 12 months were associated with a higher risk for infection. Continuous surveillance and prudent antibiotic use by healthcare professionals are important factors for effective control of ESBL associated infections.

Meier S, Weber R, Zbinden R, Ruef C, Hasse B. Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy. Infection. 2011;39:333–40. https://doi.org/10.1007/s15010-011-0132-6.CrossRefPubMed

Khadri H, Alzohairy M. High prevalence of multi-drug- resistance (MDR) and extended spectrum-lactamases (ESBL) producing bacteria among community-acquired urinary tract infections (CAUTI). J Bacteriol Res. 2009;1:105–10.

Dalgic N, Sancar M, Bayraktar B, Dincer E, Pelit S. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis. 2011;43:339–43. https://doi.org/10.3109/00365548.2011.553241.CrossRefPubMed

Fan NC, Chen HH, Chen CL, Ou LS, Lin TY, Tsai MH, et al. Rise of community-onset urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli in children. J Microbiol Immunol Infect. 2014;47:399–405. https://doi.org/10.1016/j.jmii.2013.05.006.CrossRefPubMed

Kung CH, Ku WW, Lee CH, Fung CP, Kuo SC, Chen TL, et al. Epidemiology and risk factors of community-onset urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae in a medical center in Taiwan: a prospective cohort study. J Microbiol Immunol Infect. 2015;48:168–74. https://doi.org/10.1016/j.jmii.2013.08.006.CrossRefPubMed

Nimri L. Community-acquired urinary tract infections in a rural area in Jordan: predominant uropathogens, and their antimicrobial resistance. Webmed Central Microbiol. 2010;1:1–10.

Ozcakar ZB, Yalcinkaya F, Kavaz A, Kadioglu G, Elhan AH, Aysev D, et al. Urinary tract infections owing to ESBL-producing bacteria: microorganisms change—clinical pattern does not. Acta Paediatr. 2011;100:e61–4. https://doi.org/10.1111/j.1651-2227.2011.02262.x.CrossRefPubMed

Chen PC, Chang LY, Lu CY, Shao PL, Tsai IJ, Tsau YK, et al. Drug susceptibility and treatment response of common urinary tract infection pathogens in children. J Microbiol Immunol Infect. 2014;47:478–83. https://doi.org/10.1016/j.jmii.2013.07.011.CrossRefPubMed

Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–66. https://doi.org/10.1016/S1473-3099(08)70041-0.CrossRefPubMed

10.

Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis. 2010;23:320–6.CrossRefPubMed

11.

Tratselas A, Iosifidis E, Ioannidou M, Saoulidis S, Kollios K, Antachopoulos C, et al. Outcome of urinary tract infections caused by extended spectrum beta-lactamase-producing Enterobacteriaceae in children. Pediatr Infect Dis J. 2011;30:707–10. https://doi.org/10.1097/INF.0b013e31820d7ec4.CrossRefPubMed

12.

Briongos-Figuero LS, Gómez-Traveso T, Bachiller-Luque P, Domínguez-Gil González M, Gómez-Nieto A, Palacios-Martín T, González-Sagrado M, Dueñas-Laita A, Pérez-Castrillón JL. Epidemiology, risk factors and comorbidity for urinary tract infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria. Int J Clin Pract. 2012;66:891–6. https://doi.org/10.1111/j.1742-1241.2012.02991.x.CrossRefPubMed

13.

Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D. Urinary tract infections caused by community-acquired extended-spectrum beta-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. 2013;163:1417–21. https://doi.org/10.1016/j.jpeds.2013.06.078.CrossRefPubMed

14.

Goulenok T, Ferroni A, Bille E, Lecuyer H, Join-Lambert O, Descamps P, et al. Risk factors for developing ESBL E. coli: can clinicians predict infection in patients with prior colonization? J Hosp Infect. 2013;84:294–9. https://doi.org/10.1016/j.jhin.2013.04.018.CrossRefPubMed

15.

Moor CT, Roberts SA, Simmons G, Briggs S, Morris AJ, Smith J, et al. Extended-spectrum beta-lactamase (ESBL)-producing enterobacteria: factors associated with infection in the community setting, Auckland, New Zealand. J Hosp Infect. 2008;68:355–62. https://doi.org/10.1016/j.jhin.2008.02.003.CrossRefPubMed

16.

Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect. 2010;16:147–51. https://doi.org/10.1111/j.1469-0691.2009.02941.x.CrossRefPubMed

17.

Yilmaz E, Akalin H, Ozbey S, Kordan Y, Sinirtas M, Gurcuoglu E, et al. Risk factors in community-acquired/onset urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Chemother. 2008;20:581–5. https://doi.org/10.1179/joc.2008.20.5.581.CrossRefPubMed

18.

Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; Twenty-Third Informational Supplement. Document M100-S23. Wayne: PA; 2013.

19.

Al-Bakri AG, Bustanji Y, Yousef AM. Community consumption of antibacterial drugs within the Jordanian population: sources, patterns and appropriateness. Int J Antimicrob Agents. 2005;26:389–95.CrossRefPubMed

20.

Kader AA, Angamuthu K. Extended-spectrum beta-lactamases in urinary isolates of Escherichia coli, Klebsiella pneumoniae and other gram-negative bacteria in a hospital in Eastern Province, Saudi Arabia. Saudi Med J. 2005;26:956–9.PubMed

21.

Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49:682–90. https://doi.org/10.1086/604713.CrossRefPubMed

22.

Fernando MM, Luke WA, Miththinda JK, Wickramasinghe RD, Sebastiampillai BS, Gunathilake MP, et al. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern—a hospital based cross sectional study. BMC Infect Dis. 2017;17:138. https://doi.org/10.1186/s12879-017-2250-y.CrossRefPubMedPubMedCentral

23.

Hayajneh WA, Hajj A, Hulliel F, Sarkis DK, Irani-Hakimeh N, Kazan L, et al. Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011–2013. Int J Infect Dis. 2015;35:56–61. https://doi.org/10.1016/j.ijid.2015.04.011.CrossRefPubMed

24.

Topaloglu R, Er I, Dogan BG, Bilginer Y, Ozaltin F, Besbas N, et al. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatr Nephrol. 2010;25:919–25. https://doi.org/10.1007/s00467-009-1431-3.CrossRefPubMed

Title: Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study
Authors: Basima A. Almomani
Wail A. Hayajneh
Abeer M. Ayoub
Mera A. Ababneh
Miral A. Al Momani
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 4/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-018-1148-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Clinical patterns, epidemiology and risk factors of community-acquired urinary tract infection caused by extended-spectrum beta-lactamase producers: a prospective hospital case-control study

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections

Characteristics of pulmonary mucormycosis and predictive risk factors for the outcome

Evaluation of candidemia and antifungal consumption in a large tertiary care Italian hospital over a 12-year period

Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case–case–control study

Prognostic factors and scoring model of hematological malignancies patients with bloodstream infections

Rickettsia parkeri infections diagnosed by eschar biopsy, Virginia, USA

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page